eli lilly tirzepatide Lilly's Zepbound reduces type 2 diabetes risk, study shows Eli Lilly's Tirzepatide Shows Promise
Description
It is not an FDA-approved drug and is not intended for human or animal consumption, injection, or ingestion
hazard ratio 1.60, 95% CI 1.37 to 1.87) but not after confounding factors were accounted for (0.91, 0.73 to 1.12)
Treatments Please select your treatment below Weight Loss on Your Terms
A new study based on real world data found a possible protective effect against multiple sclerosis for some of new weight loss medications.
